| Description | Didanosine (ddI) is a nucleoside reverse transcriptase inhibitor analog of adenosine (IC50: 0.49 μM). |
| In vivo | 在培养的人类肌肉细胞中,Didanosine可促使胞浆脂滴积累,增加乳酸生产,减少SDH（复合物II的一部分）和COX（复杂IV）的活性。在HIV靶细胞中,Didanosine转化为它的活性形式脱氧腺苷-5'-三磷酸（ddATP）。在解离的DRG细胞培养中,Didanosine剂量依赖性地诱导神经突数目、最长神经突中的每个神经元长度及神经突的总长度的减少。在解离的DRG神经元中,Didanosine剂量依赖性地诱导神经突回缩或轴突损失,说明去羟肌苷对发展周围神经病变有一定帮助。在培养的人TK6淋巴母细胞中,Didanosine对齐多呋定引起的胸苷激酶基因的致突变性有诱导作用。 |
| Target activity | Reverse transcriptase:0.49 μM |
| Synonyms | ddI, 去羟肌苷, 2',3'-Dideoxyinosine |
| molecular weight | 236.23 |
| Molecular formula | C10H12N4O3 |
| CAS | 69655-05-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | Ethanol: < 1 mg/mL (insoluble or slightly soluble) DMSO: 70 mg/mL (296.32 mM), Sonication is recommended. H2O: < 1 mg/mL (insoluble or slightly soluble) |
| References | 1. Benbrik E, et al. J Neurol Sci, 1997, 149(1), 19-25. 2. Perry CM, et al. Drugs, 1999, 58(6), 1099-1135. 3. Liu H, et al. Cell Biol Toxicol, 2008, 24(1), 113-121. 4. Chappell D, et al. Anesthesiology, 2007, 107(5), 776-784. 5. Walker UA, et al. Hepatology, 2004, 39(2), 311-317. 6. Fical L. Vývoj UHPLC-MS/MS metody pro analýzu vybraných antivirotik v HILIC a RP módu[J]. 2020 7. Fical L, Khalikova M, Kočová Vlčková H, et al. Determination of Antiviral Drugs and Their Metabolites Using Micro-Solid Phase Extraction and UHPLC-MS/MS in Reversed-Phase and Hydrophilic Interaction Chromatography Modes[J]. Molecules. 2021, 26(8): 2123. |
| Citations | 1. Fical L, Khalikova M, Kočová Vlčková H, et al. Determination of Antiviral Drugs and Their Metabolites Using Micro-Solid Phase Extraction and UHPLC-MS/MS in Reversed-Phase and Hydrophilic Interaction Chromatography Modes. Molecules. 2021, 26(8): 2123. |